Format

Send to

Choose Destination
Nat Rev Drug Discov. 2008 Nov;7(11):887-8. doi: 10.1038/nrd2741.

Romiplostim.

Author information

1
Douglas B. Cines is in the Department of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA. dcines@mail.med.upenn.edu

Abstract

In August 2008, romiplostim (Nplate; Amgen), a thrombopoietin receptor agonist, was approved by the US FDA for the treatment of thrombocytopaenia in patients with chronic immune thrombocytopaenic purpura who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy.

PMID:
18974747
DOI:
10.1038/nrd2741
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center